The Oncology(TOI) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.49美元 [[[0,"-0.56"],[1,"-0.71"],[2,"-0.21"],[3,"-0.35"],[4,"-0.49"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股收益单位：美元查看明细>>	归母净利润： -4387.8万美元同比增长-4.03% [[[0,"-4217.90"],[1,"-6466.30"],[2,"-1607.50"],[3,"-3007.20"],[4,"-4387.80"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u4e07\u7f8e\u5143"] 净利润单位：万美元查看明细>>	每股净资产： -0.13美元 [[[0,"0.20"],[1,"0.05"],[2,"0.06"],[3,"-0.10"],[4,"-0.13"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股净资产单位：美元查看明细>>	净资产收益率ROE(平均)：未披露
稀释每股收益： -0.49美元 [[[0,"-0.56"],[1,"-0.71"],[2,"-0.21"],[3,"-0.35"],[4,"-0.49"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 稀释每股收益单位：美元查看明细>>	营业收入： 3.61亿美元同比增长23.07% [[[0,"2.93"],[1,"3.93"],[2,"1.04"],[3,"2.24"],[4,"3.61"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u4ebf\u7f8e\u5143"] 营业收入单位：万美元查看明细>>	每股现金流： -0.29美元 [[[0,"-0.41"],[1,"-0.35"],[2,"-0.06"],[3,"-0.16"],[4,"-0.29"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股现金流单位：美元查看明细>>	总资产收益率(ROA)： -31.57% [[[0,"-11.63"],[1,"-22.01"],[2,"-31.57"]],[[0,"2025\u4e00\u5b63\u62a5"],[1,"2025\u4e2d\u62a5"],[2,"2025\u4e09\u5b63\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为美元

近期重要事件

2025-12-15	详情>> 内部人交易： Hively Brad股份减少13333.00股
2025-11-13	详情>> 股本变动：变动后总股本9838.13万股
2025-11-13	详情>> 业绩披露： 2025年三季报(累计)每股收益-0.49美元,归母净利润-4387.8万美元,同比去年增长14.77%
2025-11-13	财报披露：美东时间 2025-11-13 盘后发布财报
2025-08-13	详情>> 业绩披露： 2025年中报每股收益-0.35美元,归母净利润-3007.2万美元,同比去年增长14.97%
2025-05-14	详情>> 业绩披露： 2025年一季报每股收益-0.21美元,归母净利润-1607.5万美元,同比去年增长19.18%
2025-03-27	股东大会：将于2025-05-07召开股东大会会议内容 ▼▲ 1.Election of eight nominees named in the proxy statement to serve on the Board of Directors. The Board of Directors recommends a vote “FOR” each nominee. 2.Ratification of the appointment of BDO USA, P.C. (“BDO”) as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. The Board of Directors recommends a vote “FOR”. 3.Approval to amend the Company’s Third Amended and Restated Certificate of Incorporation to effect a reverse stock split if deemed appropriate by the Company’s Board of Directors (the “2025 Reverse Stock Split Proposal”). The Board of Directors recommends a vote “FOR”.
2025-03-26	详情>> 业绩披露： 2024年年报每股收益-0.71美元,归母净利润-6466.3万美元,同比去年增长22.16%
2024-11-13	详情>> 业绩披露： 2024年三季报(累计)每股收益-0.56美元,归母净利润-5148.1万美元,同比去年增长19.95%
2024-08-13	详情>> 业绩披露： 2024年中报每股收益-0.39美元,归母净利润-3536.8万美元,同比去年增长24.58%
2024-05-14	详情>> 业绩披露： 2024年一季报每股收益-0.22美元,归母净利润-1988.9万美元,同比去年增长33.70%
2024-05-02	股东大会：将于2024-06-13召开股东大会会议内容 ▼▲ 1.Ratification of the appointment of BDO USA, P.C. (“BDO”) as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. The Board of Directors recommends a vote “FOR”. 2.Approval, for the purposes of Nasdaq Listing Rule 5635, of the issuances of the maximum number of shares of Common Stock underlying our Secured Senior Convertible Notes and Warrants to purchase Common Stock. The Board of Directors recommends a vote “FOR”. 3.Election of nine nominees named in the proxy statement to serve on the Board of Directors. The Board of Directors recommends a vote “FOR” each nominee.
2024-03-28	详情>> 业绩披露： 2023年年报每股收益-0.92美元,归母净利润-8306.8万美元,同比去年增长-54750%
2023-11-08	详情>> 业绩披露： 2023年三季报(累计)每股收益-0.71美元,归母净利润-6431.4万美元,同比去年增长-676.34%
2023-08-09	详情>> 业绩披露： 2023年中报每股收益-0.52美元,归母净利润-4689.5万美元,同比去年增长-439.01%
2023-04-28	股东大会：将于2023-06-15召开股东大会会议内容 ▼▲ 1.Election of nine nominees named in the proxy statement to serve on the Board of Directors. The Board of Directors recommends a vote “FOR” each nominee. 2.Ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2023. The Board of Directors recommends a vote “FOR”.
2022-10-11	复牌提示： 2022-10-11 09:33:11 停牌，复牌日期 2022-10-11 09:38:11
2022-06-03	股东大会：将于2022-07-14召开股东大会会议内容 ▼▲ 1.Election of seven directors. 2.Ratification of the appointment of BDO USA LLP as the independent registered public accounting firm of the Company for 2022.

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万美元)	收入比例(%)
按业务	药房	18776.1	52.04
	病人服务	16915.4	46.89
	临床试验及其他	385.7	1.07

项目名称		营业收入(万美元)	收入比例(%)
按业务	药房	11186.6	49.89
	病人服务	10895.9	48.60
	临床试验及其他	338.3	1.51

项目名称		营业收入(万美元)	收入比例(%)
按业务	病人服务	5306.8	50.83
	药房	4929.3	47.21
	临床试验及其他	204.5	1.96

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。